<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="2">35525929</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1471-2407</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>07</Day>
            </PubDate>
          </JournalIssue>
          <Title>BMC cancer</Title>
          <ISOAbbreviation>BMC Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.</ArticleTitle>
        <Pagination>
          <StartPage>516</StartPage>
          <MedlinePgn>516</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">516</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-022-09624-y</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Approximately 20-33% of all cancer patients are treated with acid-reducing agents (ARAs), most commonly proton pump inhibitors (PPIs), to reduce gastroesophageal reflux disease symptoms. Palbociclib and ribociclib are weak bases so their solubility depends on different pH. The solubility of palbociclib dramatically decreases to &lt; 0.5 mg/ml when pH is above 4,5 but ribociclibs' solubility decreases when pH increases above 6,5. In the current study, we aimed to investigate the effects of concurrent PPIs on palbociclib and ribociclib efficacy in terms of progression-free survival in metastatic breast cancer (mBC) patients.</AbstractText>
          <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">We enrolled hormone receptor-positive, HER2-negative mBC patients treated with endocrine treatment (letrozole or fulvestrant) combined palbociclib or ribociclib alone or with PPI accompanying our observational study. During palbociclib/ribociclib therapy, patients should be treated with "concurrent PPIs" defined as all or more than half of treatment with palbociclib/ribociclib, If no PPI was applied, it was defined as 'no concurrent PPI', those who used PPI but less than half were excluded from the study. All data was collected from real-life retrospectively.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Our study included 217 patients, 105 of whom received palbociclib and 112 received ribociclib treatment. In the study population CDK inhibitor treatment was added to fulvestrant 102 patients ( 47%), to letrozole 115 patients (53%). In the Palbociclib arm fulvestrant/letrozole ratio was 53.3/46.7%, in the ribociclib arm it was 41.07/58.93%. Of 105 patients who received palbociclib, 65 were on concomitant PPI therapy, 40 were not. Of the 112 patients who received ribociclib, 61 were on concomitant PPI therapy, 51 were not. In the palbociclib group, the PFS of the patients using PPIs was shorter than the PFS of the patients not using (13.04 months vs. unreachable, p &lt; 0.001). It was determined that taking PPIs was an independent predictor of shortening PFS (p &lt; 0.001) in the multivariate analysis, In the ribociclib group, the PFS of the patients using PPIs was shorter than the PFS of the patients not using (12.64 months vs. unreachable, p = 0.003). It was determined that taking PPIs was single statistically independent predictor of shortening PFS (p = 0.003, univariate analysis).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study demonstrated that concomitant usage of PPIs was associated with shorter PFS in mBC treated with both ribociclib and especially palbociclib. If it needs to be used, PPI selection should be made carefully and low-strength PPI or other ARAs (eg H2 antagonists, antacids) should be preferred.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Eser</LastName>
            <ForeName>Kadir</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, Department of Medical Oncology, Mersin University, Çiftlikköy Kampüsü, Yenişehir, 33343, Mersin, Turkey. drkadireser@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Önder</LastName>
            <ForeName>Arif Hakan</ForeName>
            <Initials>AH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Antalya Education and Research Hospital, Antalya, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sezer</LastName>
            <ForeName>Emel</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, Department of Medical Oncology, Mersin University, Çiftlikköy Kampüsü, Yenişehir, 33343, Mersin, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Çil</LastName>
            <ForeName>Timuçin</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Adana Education and Research Hospital, Adana, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>İnal</LastName>
            <ForeName>Ali</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Mersin Education and Research Hospital, Mersin, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Öztürk</LastName>
            <ForeName>Banu</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Antalya Education and Research Hospital, Antalya, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Erçolak</LastName>
            <ForeName>Vehbi</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, Department of Medical Oncology, Mersin University, Çiftlikköy Kampüsü, Yenişehir, 33343, Mersin, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Duman</LastName>
            <ForeName>Berna Bozkurt</ForeName>
            <Initials>BB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Adana Education and Research Hospital, Adana, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Çelik</LastName>
            <ForeName>Halil</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, Department of Medical Oncology, Mersin University, Çiftlikköy Kampüsü, Yenişehir, 33343, Mersin, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Köşeci</LastName>
            <ForeName>Tolga</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Adana Education and Research Hospital, Adana, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kesen</LastName>
            <ForeName>Oğuzhan</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Adana Education and Research Hospital, Adana, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D064888">Observational Study</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>BMC Cancer</MedlineTA>
        <NlmUniqueID>100967800</NlmUniqueID>
        <ISSNLinking>1471-2407</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000631">Aminopyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054328">Proton Pump Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011687">Purines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>22X328QOC4</RegistryNumber>
          <NameOfSubstance UI="D000077267">Fulvestrant</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7LKK855W8I</RegistryNumber>
          <NameOfSubstance UI="D000077289">Letrozole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>G9ZF61LE7G</RegistryNumber>
          <NameOfSubstance UI="C500026">palbociclib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>TK8ERE8P56</RegistryNumber>
          <NameOfSubstance UI="C000589651">ribociclib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000631" MajorTopicYN="N">Aminopyridines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="Y">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077267" MajorTopicYN="N">Fulvestrant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077289" MajorTopicYN="N">Letrozole</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="Y">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054328" MajorTopicYN="Y">Proton Pump Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Breast cancer</Keyword>
        <Keyword MajorTopicYN="N">PFS</Keyword>
        <Keyword MajorTopicYN="N">Palbociclib</Keyword>
        <Keyword MajorTopicYN="N">Proton pump inhibitors</Keyword>
        <Keyword MajorTopicYN="N">Ribociclib</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>23</Hour>
          <Minute>34</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35525929</ArticleId>
        <ArticleId IdType="pmc">PMC9078089</ArticleId>
        <ArticleId IdType="doi">10.1186/s12885-022-09624-y</ArticleId>
        <ArticleId IdType="pii">10.1186/s12885-022-09624-y</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Smelick GS, et al.  Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug–drug interaction potential for molecular targeted agents in clinical development. Mol Pharm. 2013;10(11):4055–4062. doi: 10.1021/mp400403s.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/mp400403s</ArticleId>
            <ArticleId IdType="pubmed">24044612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raoul JL, et al.  Prevalence of proton pump inhibitor use among patients with cancer. JAMA Netw Open. 2021;4(6):e2113739. doi: 10.1001/jamanetworkopen.2021.13739.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamanetworkopen.2021.13739</ArticleId>
            <ArticleId IdType="pmc">PMC8209575</ArticleId>
            <ArticleId IdType="pubmed">34132796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wedemeyer R-S, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201–211. doi: 10.1007/s40264-014-0144-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40264-014-0144-0</ArticleId>
            <ArticleId IdType="pmc">PMC3975086</ArticleId>
            <ArticleId IdType="pubmed">24550106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Budha NR, et al.  Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the achilles heel of targeted therapy? Clin Pharmacol Ther. 2012;92(2):203–213. doi: 10.1038/clpt.2012.73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/clpt.2012.73</ArticleId>
            <ArticleId IdType="pubmed">22739140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mudie DM, et al.  Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state. Mol Pharm. 2014;11(9):3039–3047. doi: 10.1021/mp500210c.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/mp500210c</ArticleId>
            <ArticleId IdType="pubmed">25115349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riechelmann RP, Krzyzanowska MK. Drug interactions and oncological outcomes: a hidden adversary. Ecancermedicalscience. 2019;13:ed88. doi: 10.3332/ecancer.2019.ed88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3332/ecancer.2019.ed88</ArticleId>
            <ArticleId IdType="pmc">PMC6467454</ArticleId>
            <ArticleId IdType="pubmed">31123502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hilton JF, et al.  An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer. 2013;82(1):136–142. doi: 10.1016/j.lungcan.2013.06.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lungcan.2013.06.008</ArticleId>
            <ArticleId IdType="pubmed">23910908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumarakulasinghe NB, et al.  EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction. Oncotarget. 2016;7(51):85542. doi: 10.18632/oncotarget.13458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.13458</ArticleId>
            <ArticleId IdType="pmc">PMC5356756</ArticleId>
            <ArticleId IdType="pubmed">27907909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vishwanathan K, et al.  The effect of food or omeprazole on the pharmacokinetics of osimertinib in patients with non-small-cell lung cancer and in healthy volunteers. J Clin Pharmacol. 2018;58(4):474–484. doi: 10.1002/jcph.1035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcph.1035</ArticleId>
            <ArticleId IdType="pubmed">29178442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng V, et al.  Concomitant use of capecitabine and proton pump inhibitors - Is it safe? J Oncol Pharm Pract. 2019;25(7):1705–1711. doi: 10.1177/1078155219846952.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1078155219846952</ArticleId>
            <ArticleId IdType="pubmed">31081468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zenke Y, et al.  Clinical impact of gastric acid-suppressing medication use on the efficacy of erlotinib and gefitinib in patients with advanced non–small-cell lung cancer harboring EGFR mutations. Clin Lung Cancer. 2016;17(5):412–418. doi: 10.1016/j.cllc.2016.01.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cllc.2016.01.006</ArticleId>
            <ArticleId IdType="pubmed">26944770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corley DA. Safety and Complications of Long-Term Proton Pump Inhibitor Therapy: Getting Closer to the Truth. Gastroenterology. 2019;157(3):604–607. doi: 10.1053/j.gastro.2019.07.039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2019.07.039</ArticleId>
            <ArticleId IdType="pubmed">31378636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moayyedi P, et al.  Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157(3):682–691e2. doi: 10.1053/j.gastro.2019.05.056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2019.05.056</ArticleId>
            <ArticleId IdType="pubmed">31152740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spring LM, et al.  Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020;395(10226):817–827. doi: 10.1016/S0140-6736(20)30165-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)30165-3</ArticleId>
            <ArticleId IdType="pubmed">32145796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finn RS, et al.  Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936. doi: 10.1056/NEJMoa1607303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1607303</ArticleId>
            <ArticleId IdType="pubmed">27959613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hortobagyi GN, et al.  Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541–1547. doi: 10.1093/annonc/mdy155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy155</ArticleId>
            <ArticleId IdType="pubmed">29718092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slamon DJ, et al.  Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–2472. doi: 10.1200/JCO.2018.78.9909.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.78.9909</ArticleId>
            <ArticleId IdType="pubmed">29860922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner NC, et al.  Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–1936. doi: 10.1056/NEJMoa1810527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1810527</ArticleId>
            <ArticleId IdType="pubmed">30345905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samant TS, et al.  Ribociclib bioavailability is not affected by gastric pH changes or food intake: in silico and clinical evaluations. Clin Pharmacol Ther. 2018;104(2):374–383. doi: 10.1002/cpt.940.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cpt.940</ArticleId>
            <ArticleId IdType="pmc">PMC6099197</ArticleId>
            <ArticleId IdType="pubmed">29134635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun W, et al.  Impact of acid-reducing agents on the pharmacokinetics of palbociclib, a weak base with pH-dependent solubility, with different food intake conditions. Clin Pharmacol Drug Dev. 2017;6(6):614–626. doi: 10.1002/cpdd.356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cpdd.356</ArticleId>
            <ArticleId IdType="pubmed">28430398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hussaarts K, et al.  Clinically relevant drug interactions with multikinase inhibitors: a review. Ther Adv Med Oncol. 2019;11:1758835918818347. doi: 10.1177/1758835918818347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1758835918818347</ArticleId>
            <ArticleId IdType="pmc">PMC6322107</ArticleId>
            <ArticleId IdType="pubmed">30643582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu Y, et al.  Ribociclib population pharmacokinetics and pharmacokinetic/pharmacodynamic analysis of neutrophils in cancer patients. J Clin Pharmacol. 2021;61(8):1054–1068. doi: 10.1002/jcph.1856.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcph.1856</ArticleId>
            <ArticleId IdType="pubmed">33713359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cardoso F, et al.  4th ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 4)††these guidelines were developed by the European School of Oncology (ESO) and the European Society for Medical Oncology (ESMO) Ann Oncol. 2018;29(8):1634–1657. doi: 10.1093/annonc/mdy192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy192</ArticleId>
            <ArticleId IdType="pmc">PMC7360146</ArticleId>
            <ArticleId IdType="pubmed">30032243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willemsen AECAB, et al.  Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. Drug Discov Today. 2016;21(6):962–976. doi: 10.1016/j.drudis.2016.03.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drudis.2016.03.002</ArticleId>
            <ArticleId IdType="pubmed">26995271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Leeuwen RWF, et al.  Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014;15(8):e315–e326. doi: 10.1016/S1470-2045(13)70579-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(13)70579-5</ArticleId>
            <ArticleId IdType="pubmed">24988935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>IBRANCE®, Full Prescribing Information. 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>van Leeuwen RWF, et al.  Tyrosine kinase inhibitors and proton pump inhibitors: an evaluation of treatment options. Clin Pharmacokinet. 2017;56(7):683–688. doi: 10.1007/s40262-016-0503-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40262-016-0503-3</ArticleId>
            <ArticleId IdType="pmc">PMC5488129</ArticleId>
            <ArticleId IdType="pubmed">28101705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Del Re M, et al.  Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO open. 2021;6(5):100231. doi: 10.1016/j.esmoop.2021.100231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.esmoop.2021.100231</ArticleId>
            <ArticleId IdType="pmc">PMC8441157</ArticleId>
            <ArticleId IdType="pubmed">34509802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldstein MJ, et al.  Optimizing the therapeutic window of targeted drugs in oncology: potency-guided first-in-human studies. Clin Transl Sci. 2021;14(2):536–543. doi: 10.1111/cts.12902.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cts.12902</ArticleId>
            <ArticleId IdType="pmc">PMC7993318</ArticleId>
            <ArticleId IdType="pubmed">33048459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braal CL, et al.  Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs. 2021;81(3):317–331. doi: 10.1007/s40265-020-01461-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40265-020-01461-2</ArticleId>
            <ArticleId IdType="pmc">PMC7952354</ArticleId>
            <ArticleId IdType="pubmed">33369721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Gooijer MC, et al.  P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib. Invest New Drugs. 2015;33(5):1012–1019. doi: 10.1007/s10637-015-0266-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10637-015-0266-y</ArticleId>
            <ArticleId IdType="pubmed">26123925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martínez-Chávez A, et al.  P-glycoprotein limits ribociclib brain exposure and CYP3A4 restricts its oral bioavailability. Mol Pharm. 2019;16(9):3842–3852. doi: 10.1021/acs.molpharmaceut.9b00475.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.molpharmaceut.9b00475</ArticleId>
            <ArticleId IdType="pubmed">31329454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ollier E, et al.  In vitro and in vivo evaluation of drug–drug interaction between dabigatran and proton pump inhibitors. Fundam Clin Pharmacol. 2015;29(6):604–614. doi: 10.1111/fcp.12154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/fcp.12154</ArticleId>
            <ArticleId IdType="pubmed">26392328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang Y-H, et al.  Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment-a nationwide population-based study. Cancer Manag Res. 2019;11:8539. doi: 10.2147/CMAR.S222278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CMAR.S222278</ArticleId>
            <ArticleId IdType="pmc">PMC6756852</ArticleId>
            <ArticleId IdType="pubmed">31572008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ha VH, et al.  Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer? J Oncol Pharm Pract. 2014;21(3):194–200. doi: 10.1177/1078155214527145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1078155214527145</ArticleId>
            <ArticleId IdType="pubmed">24664477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lalani A-KA, et al.  Proton pump inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2017;15(6):724–732. doi: 10.1016/j.clgc.2017.05.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clgc.2017.05.019</ArticleId>
            <ArticleId IdType="pubmed">28645482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McAlister RK, et al.  Effect of concomitant pH-elevating medications with pazopanib on progression-free survival and overall survival in patients with metastatic renal cell carcinoma. Oncologist. 2018;23(6):686–692. doi: 10.1634/theoncologist.2017-0578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2017-0578</ArticleId>
            <ArticleId IdType="pmc">PMC6067930</ArticleId>
            <ArticleId IdType="pubmed">29487220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veerman GDM, et al.  Influence of cow’s milk and esomeprazole on the absorption of erlotinib: a randomized, crossover pharmacokinetic study in lung cancer patients. Clin Pharmacokinet. 2021;60(1):69–77. doi: 10.1007/s40262-020-00910-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40262-020-00910-1</ArticleId>
            <ArticleId IdType="pmc">PMC7808986</ArticleId>
            <ArticleId IdType="pubmed">32557346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Indini A, et al.  Impact of use of gastric-acid suppressants and oral anti-cancer agents on survival outcomes: a systematic review and meta-analysis. Cancers. 2020;12(4):998. doi: 10.3390/cancers12040998.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers12040998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma M, et al.  The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019;125(7):1155–1162. doi: 10.1002/cncr.31917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.31917</ArticleId>
            <ArticleId IdType="pmc">PMC6420393</ArticleId>
            <ArticleId IdType="pubmed">30605231</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
